- Home
- NVCR vs TWST Comparison
NVCR vs TWST Comparison
Compare NVCR & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- TWST
- Stock Information
- Founded
- NVCR 2000
- TWST 2013
- Country
- NVCR Switzerland
- TWST United States
- Employees
- NVCR N/A
- TWST N/A
- Industry
- NVCR Medical/Dental Instruments
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVCR Health Care
- TWST Health Care
- Exchange
- NVCR Nasdaq
- TWST Nasdaq
- Market Cap
- NVCR 1.9B
- TWST 1.8B
- IPO Year
- NVCR 2015
- TWST 2018
- Fundamental
- Price
- NVCR $16.69
- TWST $34.64
- Analyst Decision
- NVCR Buy
- TWST Buy
- Analyst Count
- NVCR 6
- TWST 10
- Target Price
- NVCR $32.83
- TWST $49.10
- AVG Volume (30 Days)
- NVCR 1.6M
- TWST 1.1M
- Earning Date
- NVCR 07-24-2025
- TWST 08-01-2025
- Dividend Yield
- NVCR N/A
- TWST N/A
- EPS Growth
- NVCR N/A
- TWST N/A
- EPS
- NVCR N/A
- TWST N/A
- Revenue
- NVCR $621,711,000.00
- TWST $347,680,000.00
- Revenue This Year
- NVCR $5.56
- TWST $22.58
- Revenue Next Year
- NVCR $9.19
- TWST $17.71
- P/E Ratio
- NVCR N/A
- TWST N/A
- Revenue Growth
- NVCR 18.27
- TWST 25.30
- 52 Week Low
- NVCR $14.17
- TWST $27.12
- 52 Week High
- NVCR $34.13
- TWST $60.90
- Technical
- Relative Strength Index (RSI)
- NVCR 43.44
- TWST 55.33
- Support Level
- NVCR $17.20
- TWST $33.41
- Resistance Level
- NVCR $18.02
- TWST $36.39
- Average True Range (ATR)
- NVCR 1.04
- TWST 1.97
- MACD
- NVCR -0.09
- TWST 0.62
- Stochastic Oscillator
- NVCR 15.51
- TWST 75.28
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.